JP2017510554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510554A5 JP2017510554A5 JP2016551710A JP2016551710A JP2017510554A5 JP 2017510554 A5 JP2017510554 A5 JP 2017510554A5 JP 2016551710 A JP2016551710 A JP 2016551710A JP 2016551710 A JP2016551710 A JP 2016551710A JP 2017510554 A5 JP2017510554 A5 JP 2017510554A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- alkyl
- amino
- piperidin
- phenylcyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 117
- 150000003839 salts Chemical class 0.000 claims 63
- 150000001875 compounds Chemical class 0.000 claims 53
- 125000005843 halogen group Chemical group 0.000 claims 36
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 31
- 125000003118 aryl group Chemical group 0.000 claims 30
- -1 cyanomethyl Chemical group 0.000 claims 30
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 28
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 21
- 229910052799 carbon Inorganic materials 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 19
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000000260 trans-2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])[C@]1([H])C([H])([H])[C@@]1([H])* 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- SOAHNSKFZYGGEX-BJKOFHAPSA-N (1-aminocyclobutyl)-[4-[(4-fluorophenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound FC1=CC=C(CC2(CCN(CC2)C(=O)C2(CCC2)N)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 SOAHNSKFZYGGEX-BJKOFHAPSA-N 0.000 claims 1
- SLTZFKXINVPGSG-RBUKOAKNSA-N (1-aminocyclopentyl)-[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound CC1(CCN(CC1)C(=O)C1(CCCC1)N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 SLTZFKXINVPGSG-RBUKOAKNSA-N 0.000 claims 1
- AQJLQUFCVASXPB-ZWKOTPCHSA-N (1-methylimidazol-4-yl)-[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound CC1(CCN(CC1)C(=O)C=1N=CN(C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 AQJLQUFCVASXPB-ZWKOTPCHSA-N 0.000 claims 1
- HXBXFCQWRMIMLT-VQTJNVASSA-N (1R,2S)-N-[[1-[(4-fluorophenyl)methyl]azetidin-3-yl]methyl]-2-phenylcyclopropan-1-amine Chemical compound FC1=CC=C(CN2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 HXBXFCQWRMIMLT-VQTJNVASSA-N 0.000 claims 1
- VONUFLPVRCWPKX-RBUKOAKNSA-N (1R,2S)-N-[[4-(methoxymethyl)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-4-yl]methyl]-2-phenylcyclopropan-1-amine Chemical compound COCC1(CCN(CC1)S(=O)(=O)C1=NN(C=C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 VONUFLPVRCWPKX-RBUKOAKNSA-N 0.000 claims 1
- OZAONMXVFGFFDB-VQTJNVASSA-N (1R,2S)-N-[[4-(methoxymethyl)-1-(1-methylpyrazol-4-yl)sulfonylpiperidin-4-yl]methyl]-2-phenylcyclopropan-1-amine Chemical compound COCC1(CCN(CC1)S(=O)(=O)C=1C=NN(C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 OZAONMXVFGFFDB-VQTJNVASSA-N 0.000 claims 1
- XVKYTMDZBYKDLP-RBUKOAKNSA-N (1R,2S)-N-[[4-(methoxymethyl)-1-(2-methylpyrazol-3-yl)sulfonylpiperidin-4-yl]methyl]-2-phenylcyclopropan-1-amine Chemical compound COCC1(CCN(CC1)S(=O)(=O)C1=CC=NN1C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 XVKYTMDZBYKDLP-RBUKOAKNSA-N 0.000 claims 1
- VITZMUSBMJOMAU-ZWKOTPCHSA-N (2-aminopyrimidin-5-yl)-[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound CC1(CCN(CC1)C(=O)C=1C=NC(=NC1)N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 VITZMUSBMJOMAU-ZWKOTPCHSA-N 0.000 claims 1
- ADXGOWHSMAENJW-RBUKOAKNSA-N (3-fluorophenyl)-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methanone Chemical compound FC=1C=C(C(=O)N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC1 ADXGOWHSMAENJW-RBUKOAKNSA-N 0.000 claims 1
- VSNYMMTZRZKBMV-RBUKOAKNSA-N (3-hydroxyazetidin-1-yl)-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCC1(CCN(CC1)C(=O)N1CC(C1)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 VSNYMMTZRZKBMV-RBUKOAKNSA-N 0.000 claims 1
- LFYBHODARDYZBG-VQTJNVASSA-N (3-methoxyphenyl)-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methanone Chemical compound COC=1C=C(C(=O)N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC1 LFYBHODARDYZBG-VQTJNVASSA-N 0.000 claims 1
- ZWVPAXGAELUSCM-JLMCIHFGSA-N (3-methoxypiperidin-1-yl)-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methanone Chemical compound COC1CN(CCC1)C(=O)N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ZWVPAXGAELUSCM-JLMCIHFGSA-N 0.000 claims 1
- QZWXAWCOMNELDT-YDUIRMPASA-N (3-phenoxypiperidin-1-yl)-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methanone Chemical compound O(C1=CC=CC=C1)C1CN(CCC1)C(=O)N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 QZWXAWCOMNELDT-YDUIRMPASA-N 0.000 claims 1
- XPQIIEXKHBFDQX-RBUKOAKNSA-N (4-fluorophenyl)-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methanone Chemical compound FC1=CC=C(C(=O)N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 XPQIIEXKHBFDQX-RBUKOAKNSA-N 0.000 claims 1
- CHMTVVVUSLEWPW-XZOQPEGZSA-N (4-hydroxy-4-phenylpiperidin-1-yl)-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methanone Chemical compound C1(=CC=CC=C1)C1(CCN(CC1)C(=O)N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)O CHMTVVVUSLEWPW-XZOQPEGZSA-N 0.000 claims 1
- QIQCCTGHPWVZSM-LEWJYISDSA-N (4-hydroxypiperidin-1-yl)-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCC1(CCN(CC1)C(=O)N1CCC(CC1)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 QIQCCTGHPWVZSM-LEWJYISDSA-N 0.000 claims 1
- FWIVWIBIZXMCNC-DOTOQJQBSA-N (5-amino-1H-pyrazol-4-yl)-[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound CC1(CCN(CC1)C(=O)C=1C(=NNC1)N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 FWIVWIBIZXMCNC-DOTOQJQBSA-N 0.000 claims 1
- SLBPMFIYCBPGGO-XUZZJYLKSA-N (5-fluorospiro[1,2-dihydroindole-3,4'-piperidine]-1'-yl)-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methanone Chemical compound FC=1C=C2C3(CNC2=CC1)CCN(CC3)C(=O)N3CC(C3)CN[C@H]3[C@@H](C3)C3=CC=CC=C3 SLBPMFIYCBPGGO-XUZZJYLKSA-N 0.000 claims 1
- KCHQHSGAMGHQSK-PKOBYXMFSA-N (6-aminopyridazin-3-yl)-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCC1(CCN(CC1)C(=O)C1=CC=C(N=N1)N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 KCHQHSGAMGHQSK-PKOBYXMFSA-N 0.000 claims 1
- JOOYFEVIUSPWJE-FUHWJXTLSA-N (6-aminopyridazin-3-yl)-[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound CC1(CCN(CC1)C(=O)C1=CC=C(N=N1)N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 JOOYFEVIUSPWJE-FUHWJXTLSA-N 0.000 claims 1
- FPSQMGPANOOROJ-LEWJYISDSA-N 1-[(4-fluorophenyl)methyl]-N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine Chemical compound FC1=CC=C(CN2CCC(CC2)N[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 FPSQMGPANOOROJ-LEWJYISDSA-N 0.000 claims 1
- VJFSXNAKZDCINM-RBUKOAKNSA-N 1-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidine-1-carbonyl]piperidine-4-carbonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C(=O)N1CCC(CC1)C#N VJFSXNAKZDCINM-RBUKOAKNSA-N 0.000 claims 1
- ZBPAYLBHWULFPT-RBUKOAKNSA-N 1-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidine-1-carbonyl]cyclopropane-1-carbonitrile Chemical compound COCC1(CCN(CC1)C(=O)C1(CC1)C#N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ZBPAYLBHWULFPT-RBUKOAKNSA-N 0.000 claims 1
- GYNFNBWRBNJQAY-BJKOFHAPSA-N 1-[[4-(cyclobutylmethoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C1(CCC1)COCC1(CCN(CC1)CC1(CCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 GYNFNBWRBNJQAY-BJKOFHAPSA-N 0.000 claims 1
- HAOQZWCUJFVTPM-XZOQPEGZSA-N 1-[[4-(cyclobutylmethoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C1(CCC1)COCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 HAOQZWCUJFVTPM-XZOQPEGZSA-N 0.000 claims 1
- IJWMKGNGHJPQRQ-LOSJGSFVSA-N 1-[[4-(cyclohexyloxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C1(CCCCC1)OCC1(CCN(CC1)CC1(CCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 IJWMKGNGHJPQRQ-LOSJGSFVSA-N 0.000 claims 1
- LHDBDRJSXYLAEY-BJKOFHAPSA-N 1-[[4-(cyclohexyloxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C1(CCCCC1)OCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 LHDBDRJSXYLAEY-BJKOFHAPSA-N 0.000 claims 1
- SFNUNNPWVAFSIB-LEWJYISDSA-N 1-[[4-(ethoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C(C)OCC1(CCN(CC1)CC1(CCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 SFNUNNPWVAFSIB-LEWJYISDSA-N 0.000 claims 1
- FITOWUHOVCAWQI-VQTJNVASSA-N 1-[[4-(ethoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(C)OCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 FITOWUHOVCAWQI-VQTJNVASSA-N 0.000 claims 1
- NKYSMFSRMSTFJE-QYAPWVIVSA-N 1-[[4-(methoxymethyl)-4-[1-[[(1R,2S)-2-phenylcyclopropyl]amino]ethyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound COCC1(CCN(CC1)CC1(CCC1)C(=O)O)C(C)N[C@H]1[C@@H](C1)C1=CC=CC=C1 NKYSMFSRMSTFJE-QYAPWVIVSA-N 0.000 claims 1
- WBPWDDPSYSUQJA-VQTJNVASSA-N 1-[[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound COCC1(CCN(CC1)CC1(CCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 WBPWDDPSYSUQJA-VQTJNVASSA-N 0.000 claims 1
- OUHFLPHJVJYMBF-LEWJYISDSA-N 1-[[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopentane-1-carboxylic acid Chemical compound COCC1(CCN(CC1)CC1(CCCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 OUHFLPHJVJYMBF-LEWJYISDSA-N 0.000 claims 1
- WXVYOBVVDHYKDR-RBUKOAKNSA-N 1-[[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound COCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 WXVYOBVVDHYKDR-RBUKOAKNSA-N 0.000 claims 1
- SLGVTHWQMQIMBW-UHFFFAOYSA-N 1-[[4-(methoxymethyl)-4-[[[2-(2-methoxyphenyl)cyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound COCC1(CCN(CC1)CC1(CCC1)C(=O)O)CNC1C(C1)C1=C(C=CC=C1)OC SLGVTHWQMQIMBW-UHFFFAOYSA-N 0.000 claims 1
- CLNSMUQWWKZARQ-LOSJGSFVSA-N 1-[[4-[(2-cyanophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C(#N)C1=C(OCC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC=C1 CLNSMUQWWKZARQ-LOSJGSFVSA-N 0.000 claims 1
- GOIZVSLYXPEOOA-BJKOFHAPSA-N 1-[[4-[(2-cyanophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(#N)C1=C(OCC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC=C1 GOIZVSLYXPEOOA-BJKOFHAPSA-N 0.000 claims 1
- OBPJTNQRLCABSA-LADGPHEKSA-N 1-[[4-[(2-fluorophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound FC1=C(OCC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC=C1 OBPJTNQRLCABSA-LADGPHEKSA-N 0.000 claims 1
- STZLGHHZQLGPOW-JTHBVZDNSA-N 1-[[4-[(2-fluorophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound FC1=C(OCC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC=C1 STZLGHHZQLGPOW-JTHBVZDNSA-N 0.000 claims 1
- SGSBYMOOZWAAGR-IZZNHLLZSA-N 1-[[4-[(3-cyanophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C(#N)C=1C=C(OCC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC1 SGSBYMOOZWAAGR-IZZNHLLZSA-N 0.000 claims 1
- HDCRRCYDJGFTFR-LOSJGSFVSA-N 1-[[4-[(3-cyanophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(#N)C=1C=C(OCC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC1 HDCRRCYDJGFTFR-LOSJGSFVSA-N 0.000 claims 1
- IXTOKMCDFLOINY-IZZNHLLZSA-N 1-[[4-[(3-cyanophenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C(#N)C=1C=C(CC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC1 IXTOKMCDFLOINY-IZZNHLLZSA-N 0.000 claims 1
- KIKTUCZVZVPEKU-LOSJGSFVSA-N 1-[[4-[(3-cyanophenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(#N)C=1C=C(CC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC1 KIKTUCZVZVPEKU-LOSJGSFVSA-N 0.000 claims 1
- DQTLXBJKIIPAFN-LOSJGSFVSA-N 1-[[4-[(3-fluorophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound FC=1C=C(OCC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC1 DQTLXBJKIIPAFN-LOSJGSFVSA-N 0.000 claims 1
- XVTZUVVVHLXQFD-BJKOFHAPSA-N 1-[[4-[(3-fluorophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound FC=1C=C(OCC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=CC1 XVTZUVVVHLXQFD-BJKOFHAPSA-N 0.000 claims 1
- SEPRCDKARFRTCZ-RBBKRZOGSA-N 1-[[4-[(3-fluoropyridin-2-yl)oxymethyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound FC=1C(=NC=CC1)OCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 SEPRCDKARFRTCZ-RBBKRZOGSA-N 0.000 claims 1
- HKTPEQAIQDYVFR-UKILVPOCSA-N 1-[[4-[(4-cyano-2-fluorophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C(#N)C1=CC(=C(OCC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1)F HKTPEQAIQDYVFR-UKILVPOCSA-N 0.000 claims 1
- HNQYHGLBDNEEMO-LADGPHEKSA-N 1-[[4-[(4-cyano-2-fluorophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(#N)C1=CC(=C(OCC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1)F HNQYHGLBDNEEMO-LADGPHEKSA-N 0.000 claims 1
- HMOLISQCXABYDC-JUERFOTFSA-N 1-[[4-[(4-cyano-2-fluorophenyl)methoxymethyl]-4-[[[(1R)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C1CC1(CN2CCC(CC2)(CN[C@@H]3CC3C4=CC=CC=C4)COCC5=C(C=C(C=C5)C#N)F)C(=O)O HMOLISQCXABYDC-JUERFOTFSA-N 0.000 claims 1
- YMXWHDVZAOIUJF-IZZNHLLZSA-N 1-[[4-[(4-cyanophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C(#N)C1=CC=C(OCC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 YMXWHDVZAOIUJF-IZZNHLLZSA-N 0.000 claims 1
- ZNFGLRCQVARIBN-LOSJGSFVSA-N 1-[[4-[(4-cyanophenoxy)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(#N)C1=CC=C(OCC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 ZNFGLRCQVARIBN-LOSJGSFVSA-N 0.000 claims 1
- YTHLDYPCWTWELT-LOSJGSFVSA-N 1-[[4-[(4-cyanophenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(#N)C1=CC=C(CC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 YTHLDYPCWTWELT-LOSJGSFVSA-N 0.000 claims 1
- CZXUWYSCUHUMFD-LOSJGSFVSA-N 1-[[4-[(4-fluorophenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound FC1=CC=C(CC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 CZXUWYSCUHUMFD-LOSJGSFVSA-N 0.000 claims 1
- XWFREVSRYGFJQR-BJKOFHAPSA-N 1-[[4-[(4-fluorophenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound FC1=CC=C(CC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 XWFREVSRYGFJQR-BJKOFHAPSA-N 0.000 claims 1
- WFZXDEDOAIIMGM-IZZNHLLZSA-N 1-[[4-[(4-methoxyphenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound COC1=CC=C(CC2(CCN(CC2)CC2(CCC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 WFZXDEDOAIIMGM-IZZNHLLZSA-N 0.000 claims 1
- SSIUDNSOYXROLU-LOSJGSFVSA-N 1-[[4-[(4-methoxyphenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound COC1=CC=C(CC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 SSIUDNSOYXROLU-LOSJGSFVSA-N 0.000 claims 1
- QVJOPJGPADNOQV-BJKOFHAPSA-N 1-[[4-[(5-fluoropyridin-2-yl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound FC=1C=CC(=NC1)CC1(CCN(CC1)CC1(CCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 QVJOPJGPADNOQV-BJKOFHAPSA-N 0.000 claims 1
- BCMVRSCBEDJBSN-XZOQPEGZSA-N 1-[[4-[(5-fluoropyridin-2-yl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound FC=1C=CC(=NC1)CC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 BCMVRSCBEDJBSN-XZOQPEGZSA-N 0.000 claims 1
- GDPDYDINFDPESI-FCHUYYIVSA-N 1-[[4-[(5-fluoropyridin-2-yl)oxymethyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound FC=1C=CC(=NC1)OCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 GDPDYDINFDPESI-FCHUYYIVSA-N 0.000 claims 1
- WVFVNSZFHXRVGY-LEWJYISDSA-N 1-[[4-[(5-fluoropyrimidin-2-yl)oxymethyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound FC=1C=NC(=NC1)OCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 WVFVNSZFHXRVGY-LEWJYISDSA-N 0.000 claims 1
- OYIDQPBZECASPU-IZZNHLLZSA-N 1-[[4-[[4-(cyanomethyl)phenyl]methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(#N)CC1=CC=C(CC2(CCN(CC2)CC2(CC2)C(=O)O)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 OYIDQPBZECASPU-IZZNHLLZSA-N 0.000 claims 1
- VMYZUYCZEBHDGB-JTHBVZDNSA-N 1-[[4-[[6-(methylcarbamoyl)pyridin-2-yl]oxymethyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound CNC(=O)C1=CC=CC(=N1)OCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 VMYZUYCZEBHDGB-JTHBVZDNSA-N 0.000 claims 1
- ACAUTIPGWZOLCK-LADGPHEKSA-N 1-[[4-[[6-(methylcarbamoyl)pyridin-3-yl]oxymethyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound CNC(=O)C1=CC=C(C=N1)OCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ACAUTIPGWZOLCK-LADGPHEKSA-N 0.000 claims 1
- DBQQHVYQBKLGRT-AZUAARDMSA-N 1-[[4-[[[(1R,2S)-2-(2-fluorophenyl)cyclopropyl]amino]methyl]-4-(methoxymethyl)piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound FC1=C(C=CC=C1)[C@H]1[C@@H](C1)NCC1(CCN(CC1)CC1(CCC1)C(=O)O)COC DBQQHVYQBKLGRT-AZUAARDMSA-N 0.000 claims 1
- LGJFYWUUUVYYBG-FXAWDEMLSA-N 1-[[4-[[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]methyl]-4-(methoxymethyl)piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound FC=1C=C(C=CC1F)[C@H]1[C@@H](C1)NCC1(CCN(CC1)CC1(CCC1)C(=O)O)COC LGJFYWUUUVYYBG-FXAWDEMLSA-N 0.000 claims 1
- OZJHFMNLEWWPQT-VQTJNVASSA-N 1-[[4-[[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]methyl]-4-(methoxymethyl)piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound FC1=CC=C(C=C1)[C@H]1[C@@H](C1)NCC1(CCN(CC1)CC1(CCC1)C(=O)O)COC OZJHFMNLEWWPQT-VQTJNVASSA-N 0.000 claims 1
- MEVFWXXREJLLKR-IZZNHLLZSA-N 1-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]-4-(phenylmethoxymethyl)piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound C(C1=CC=CC=C1)OCC1(CCN(CC1)CC1(CCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 MEVFWXXREJLLKR-IZZNHLLZSA-N 0.000 claims 1
- GXEBZZCIQAQLMQ-LOSJGSFVSA-N 1-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]-4-(phenylmethoxymethyl)piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound C(C1=CC=CC=C1)OCC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 GXEBZZCIQAQLMQ-LOSJGSFVSA-N 0.000 claims 1
- MIYZGIWUTFPQLS-RBUKOAKNSA-N 1-[[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclobutane-1-carboxylic acid Chemical compound CC1(CCN(CC1)CC1(CCC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 MIYZGIWUTFPQLS-RBUKOAKNSA-N 0.000 claims 1
- MCQZAGJMVRHLNR-ZWKOTPCHSA-N 1-[[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]cyclopropane-1-carboxylic acid Chemical compound CC1(CCN(CC1)CC1(CC1)C(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 MCQZAGJMVRHLNR-ZWKOTPCHSA-N 0.000 claims 1
- WYSUAYRVRIGXKK-FCHUYYIVSA-N 2-[1-(3-fluorobenzoyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-4-yl]acetonitrile Chemical compound FC=1C=C(C(=O)N2CCC(CC2)(CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=CC1 WYSUAYRVRIGXKK-FCHUYYIVSA-N 0.000 claims 1
- OVCGXEPMQDYOBF-XZOQPEGZSA-N 2-[1-[(3-fluorophenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-4-yl]acetonitrile Chemical compound FC=1C=C(CN2CCC(CC2)(CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC#N)C=CC1 OVCGXEPMQDYOBF-XZOQPEGZSA-N 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- FMKACORRVRXVQK-RBBKRZOGSA-N 3-[3-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidine-1-carbonyl]pyrazol-1-yl]propanenitrile Chemical compound COCC1(CCN(CC1)C(=O)C1=NN(C=C1)CCC#N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 FMKACORRVRXVQK-RBBKRZOGSA-N 0.000 claims 1
- BAEORYGZLNNIGE-VQTJNVASSA-N 3-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidine-1-carbonyl]benzonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C(=O)C=1C=C(C#N)C=CC1 BAEORYGZLNNIGE-VQTJNVASSA-N 0.000 claims 1
- FYXGBMSOQNXDQJ-FCHUYYIVSA-N 3-[4-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidine-1-carbonyl]pyrazol-1-yl]propanenitrile Chemical compound COCC1(CCN(CC1)C(=O)C=1C=NN(C1)CCC#N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 FYXGBMSOQNXDQJ-FCHUYYIVSA-N 0.000 claims 1
- IOWDJGVHBKRLIL-URLMMPGGSA-N 3-[[1-[(3-methoxyphenyl)methyl]-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-4-yl]methyl]benzoic acid Chemical compound COC=1C=C(CN2CCC(CC2)(CN[C@H]2[C@@H](C2)C2=CC=CC=C2)CC=2C=C(C(=O)O)C=CC2)C=CC1 IOWDJGVHBKRLIL-URLMMPGGSA-N 0.000 claims 1
- AQOCSQCRPHYXJA-LEWJYISDSA-N 3-[[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methyl]benzonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)CC=1C=C(C#N)C=CC1 AQOCSQCRPHYXJA-LEWJYISDSA-N 0.000 claims 1
- NACDKNRYQKXKCP-LEWJYISDSA-N 3-[[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]methyl]benzoic acid Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)CC=1C=C(C(=O)O)C=CC1 NACDKNRYQKXKCP-LEWJYISDSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- SLQDFNDBGAIKNM-VQTJNVASSA-N 4-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidine-1-carbonyl]benzonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C(=O)C1=CC=C(C#N)C=C1 SLQDFNDBGAIKNM-VQTJNVASSA-N 0.000 claims 1
- CVJJZHUTZZHAJP-VQTJNVASSA-N 4-[[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methyl]benzoic acid Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)CC1=CC=C(C(=O)O)C=C1 CVJJZHUTZZHAJP-VQTJNVASSA-N 0.000 claims 1
- DIBARSFQWDZRHK-LEWJYISDSA-N 4-[[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]methyl]benzonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)CC1=CC=C(C#N)C=C1 DIBARSFQWDZRHK-LEWJYISDSA-N 0.000 claims 1
- LMGVADYWCZXMPT-XZOQPEGZSA-N 4-[[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]benzoic acid Chemical compound COCC1(CCN(CC1)CC1=CC=C(C(=O)O)C=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 LMGVADYWCZXMPT-XZOQPEGZSA-N 0.000 claims 1
- LCWWUXPLIBQAEP-LEWJYISDSA-N 4-[[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]methyl]benzoic acid Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)CC1=CC=C(C(=O)O)C=C1 LCWWUXPLIBQAEP-LEWJYISDSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- MTLSCBAYCRXGHN-BJKOFHAPSA-N 4-phenyl-1-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidine-1-carbonyl]piperidine-4-carbonitrile Chemical compound C1(=CC=CC=C1)C1(CCN(CC1)C(=O)N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)C#N MTLSCBAYCRXGHN-BJKOFHAPSA-N 0.000 claims 1
- JXDWUMXFIZDQFJ-RBUKOAKNSA-N 5-[[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]pyrimidin-2-amine Chemical compound CC1(CCN(CC1)CC=1C=NC(=NC1)N)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 JXDWUMXFIZDQFJ-RBUKOAKNSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- DGZISEXGDODLKG-XXTHSBEZSA-N COCC1(CCN(CC1)C(=O)[C@@H]1CC[C@H](CC1)CO)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound COCC1(CCN(CC1)C(=O)[C@@H]1CC[C@H](CC1)CO)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 DGZISEXGDODLKG-XXTHSBEZSA-N 0.000 claims 1
- DGZISEXGDODLKG-FCJDFRRUSA-N COCC1(CCN(CC1)C(=O)[C@H]1CC[C@H](CC1)CO)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound COCC1(CCN(CC1)C(=O)[C@H]1CC[C@H](CC1)CO)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 DGZISEXGDODLKG-FCJDFRRUSA-N 0.000 claims 1
- SZSRKMLBWCKQAN-XMMISQBUSA-N COc1ccc(CC2(CN[C@@H]3CC3c3ccccc3)CCN(CC3(CCC3)C(O)=O)CC2)cn1 Chemical compound COc1ccc(CC2(CN[C@@H]3CC3c3ccccc3)CCN(CC3(CCC3)C(O)=O)CC2)cn1 SZSRKMLBWCKQAN-XMMISQBUSA-N 0.000 claims 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- UXGQEZATTDUBAX-PGXSJUQOSA-N FC1=CC=C(CC2(CCN(CC2)C(=O)[C@@H]2CC[C@H](CC2)N)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 Chemical compound FC1=CC=C(CC2(CCN(CC2)C(=O)[C@@H]2CC[C@H](CC2)N)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)C=C1 UXGQEZATTDUBAX-PGXSJUQOSA-N 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- LNBASASAAMTZTE-QFBILLFUSA-N N-(2-fluorophenyl)-3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidine-1-carboxamide Chemical compound FC1=C(C=CC=C1)NC(=O)N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 LNBASASAAMTZTE-QFBILLFUSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- VQUORXBKSDKRNW-BBALPUGFSA-N O[C@H]1CC[C@H](CC1)N1C([C@@]2(CC1)CN(CCC2)C(=O)N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)=O Chemical compound O[C@H]1CC[C@H](CC1)N1C([C@@]2(CC1)CN(CCC2)C(=O)N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)=O VQUORXBKSDKRNW-BBALPUGFSA-N 0.000 claims 1
- VQUORXBKSDKRNW-KCALTQBLSA-N O[C@H]1CC[C@H](CC1)N1C([C@]2(CC1)CN(CCC2)C(=O)N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)=O Chemical compound O[C@H]1CC[C@H](CC1)N1C([C@]2(CC1)CN(CCC2)C(=O)N2CC(C2)CN[C@H]2[C@@H](C2)C2=CC=CC=C2)=O VQUORXBKSDKRNW-KCALTQBLSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- ZBNKUMQFMLURKJ-QHAWAJNXSA-N [(3R)-3-hydroxypiperidin-1-yl]-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCC1(CCN(CC1)C(=O)N1C[C@@H](CCC1)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ZBNKUMQFMLURKJ-QHAWAJNXSA-N 0.000 claims 1
- ZBNKUMQFMLURKJ-PCCBWWKXSA-N [(3S)-3-hydroxypiperidin-1-yl]-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCC1(CCN(CC1)C(=O)N1C[C@H](CCC1)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ZBNKUMQFMLURKJ-PCCBWWKXSA-N 0.000 claims 1
- CKKZDFCEIRWAGI-SLFFLAALSA-N [(3S)-3-hydroxypyrrolidin-1-yl]-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCC1(CCN(CC1)C(=O)N1C[C@H](CC1)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 CKKZDFCEIRWAGI-SLFFLAALSA-N 0.000 claims 1
- MEZMPQNZPSOWPY-PZJWPPBQSA-N [1-(2-hydroxyethyl)pyrazol-3-yl]-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCC1(CCN(CC1)C(=O)C1=NN(C=C1)CCO)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 MEZMPQNZPSOWPY-PZJWPPBQSA-N 0.000 claims 1
- QMACINFHUYISJD-LEWJYISDSA-N [1-(2-hydroxyethyl)pyrazol-4-yl]-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCC1(CCN(CC1)C(=O)C=1C=NN(C1)CCO)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 QMACINFHUYISJD-LEWJYISDSA-N 0.000 claims 1
- JYVXKQLLHLQPIH-FCHUYYIVSA-N [1-(2-methoxyethyl)pyrazol-4-yl]-[4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methanone Chemical compound COCCN1N=CC(=C1)C(=O)N1CCC(CC1)(COC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 JYVXKQLLHLQPIH-FCHUYYIVSA-N 0.000 claims 1
- FHHGKYSBSTWQBX-ZWKOTPCHSA-N [3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]-[4-(trifluoromethyl)piperidin-1-yl]methanone Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C(=O)N1CCC(CC1)C(F)(F)F FHHGKYSBSTWQBX-ZWKOTPCHSA-N 0.000 claims 1
- IUHJQKHTQDCZLQ-RBUKOAKNSA-N [4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]-(1-methylimidazol-4-yl)methanone Chemical compound COCC1(CCN(CC1)C(=O)C=1N=CN(C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 IUHJQKHTQDCZLQ-RBUKOAKNSA-N 0.000 claims 1
- ZUFSMGCSSVHSJM-FCHUYYIVSA-N [4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]-(1-methylpiperidin-4-yl)methanone Chemical compound COCC1(CCN(CC1)C(=O)C1CCN(CC1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ZUFSMGCSSVHSJM-FCHUYYIVSA-N 0.000 claims 1
- LLVPXXNIRVANJU-AZUAARDMSA-N [4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]-(1-methylpyrazol-3-yl)methanone Chemical compound COCC1(CCN(CC1)C(=O)C1=NN(C=C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 LLVPXXNIRVANJU-AZUAARDMSA-N 0.000 claims 1
- DBDHOHCMOZHHFR-VQTJNVASSA-N [4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]-(1-methylpyrazol-4-yl)methanone Chemical compound COCC1(CCN(CC1)C(=O)C=1C=NN(C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 DBDHOHCMOZHHFR-VQTJNVASSA-N 0.000 claims 1
- FWASKGAQDIPKIB-FCHUYYIVSA-N [4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]-(4-methoxypiperidin-1-yl)methanone Chemical compound COCC1(CCN(CC1)C(=O)N1CCC(CC1)OC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 FWASKGAQDIPKIB-FCHUYYIVSA-N 0.000 claims 1
- ZGXUHOYYYNOPGD-LEWJYISDSA-N [4-(methoxymethyl)-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound COCC1(CCN(CC1)C(=O)N1CCN(CC1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ZGXUHOYYYNOPGD-LEWJYISDSA-N 0.000 claims 1
- PTBCSCXZIMKNCI-PKOBYXMFSA-N [4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]-(1-methylpyrazol-3-yl)methanone Chemical compound CC1(CCN(CC1)C(=O)C1=NN(C=C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 PTBCSCXZIMKNCI-PKOBYXMFSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939488P | 2014-02-13 | 2014-02-13 | |
| US61/939,488 | 2014-02-13 | ||
| US201462061283P | 2014-10-08 | 2014-10-08 | |
| US62/061,283 | 2014-10-08 | ||
| PCT/US2015/015706 WO2015123465A1 (en) | 2014-02-13 | 2015-02-12 | Cyclopropylamines as lsd1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019185892A Division JP6883635B2 (ja) | 2014-02-13 | 2019-10-09 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510554A JP2017510554A (ja) | 2017-04-13 |
| JP2017510554A5 true JP2017510554A5 (enExample) | 2018-03-29 |
| JP6602778B2 JP6602778B2 (ja) | 2019-11-06 |
Family
ID=52589819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551710A Active JP6602778B2 (ja) | 2014-02-13 | 2015-02-12 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| JP2019185892A Expired - Fee Related JP6883635B2 (ja) | 2014-02-13 | 2019-10-09 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019185892A Expired - Fee Related JP6883635B2 (ja) | 2014-02-13 | 2019-10-09 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
Country Status (32)
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3030323B1 (en) | 2013-08-06 | 2019-04-24 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| US9493450B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| ES3005884T3 (en) | 2015-02-12 | 2025-03-17 | Imago Biosciences Inc | A kdm1a inhibitor and its use in therapy |
| PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
| US20180284095A1 (en) | 2015-06-12 | 2018-10-04 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| SG10202001219UA (en) * | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| WO2017079476A1 (en) | 2015-11-05 | 2017-05-11 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
| US9809541B2 (en) | 2015-12-29 | 2017-11-07 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| CN107200706A (zh) | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| US11034991B2 (en) | 2016-03-16 | 2021-06-15 | Oryzon Genomics S.A. | Methods to determine KDM1A target engagement and chemoprobes useful therefor |
| CN109414410B (zh) * | 2016-04-22 | 2022-08-12 | 因赛特公司 | Lsd1抑制剂的制剂 |
| WO2017195216A1 (en) | 2016-05-09 | 2017-11-16 | Jubilant Biosys Limited | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors |
| CN107459476B (zh) * | 2016-06-03 | 2022-06-24 | 中国科学院上海药物研究所 | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 |
| WO2018035259A1 (en) * | 2016-08-16 | 2018-02-22 | Imago Biosciences, Inc. | Methods and processes for the preparation of kdm1a inhibitors |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| WO2018137644A1 (zh) * | 2017-01-24 | 2018-08-02 | 南京明德新药研发股份有限公司 | Lsd1抑制剂及其制备方法和应用 |
| CN106860453A (zh) * | 2017-02-17 | 2017-06-20 | 杨燕 | 一种治疗溃疡性结肠炎的药物组合物 |
| US11168082B2 (en) | 2017-05-15 | 2021-11-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors |
| CA3071804A1 (en) | 2017-08-03 | 2019-02-07 | Oryzon Genomics, S.A. | Use of a kdm1a inhibitor in the treatment of behavior alterations |
| US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| IL279260B2 (en) | 2018-05-11 | 2024-10-01 | Imago Biosciences Inc | Kdm1a inhibitors for the treatment of disease |
| EP3794003A1 (en) | 2018-05-15 | 2021-03-24 | The Regents Of The University Of Michigan | Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| HRP20260110T1 (hr) | 2019-03-20 | 2026-03-13 | Oryzon Genomics, S.A. | Vafidemstat za liječenje neagresivnih simptoma graničnog poremećaja osobnosti |
| CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| CN114502561B (zh) * | 2019-09-29 | 2023-12-26 | 南昌弘益药业有限公司 | Lsd1抑制剂 |
| JP7626783B2 (ja) * | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| MX2023011779A (es) | 2021-04-08 | 2023-11-22 | Oryzon Genomics Sa | Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides. |
| JP2024534781A (ja) | 2021-08-18 | 2024-09-26 | ケモセントリックス，インコーポレイティド | Ｃｃｒ６阻害剤としてのアリールスルホニル（ヒドロキシ）ピペリジン |
| CA3229226A1 (en) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl compounds as ccr6 inhibitors |
| WO2023067058A1 (en) | 2021-10-20 | 2023-04-27 | Queen Mary University Of London | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
| GB202115017D0 (en) | 2021-10-20 | 2021-12-01 | Univ London Queen Mary | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| US20250275969A1 (en) | 2022-05-09 | 2025-09-04 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| CN118787751A (zh) * | 2023-04-12 | 2024-10-18 | 中国科学院上海药物研究所 | Lsd1抑制剂与药物联用治疗癌症的用途 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (321)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7013068A (enExample) | 1969-09-17 | 1971-03-19 | ||
| US4537889A (en) | 1982-12-27 | 1985-08-27 | Eli Lilly And Company | Inotropic agents |
| US4625040A (en) | 1984-09-24 | 1986-11-25 | Pennwalt Corporation | N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives |
| US4614810A (en) * | 1984-09-24 | 1986-09-30 | Pennwalt Corporation | 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof |
| FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
| JPH032778Y2 (enExample) | 1986-12-15 | 1991-01-24 | ||
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| JP2844351B2 (ja) | 1989-07-13 | 1999-01-06 | 株式会社科薬 | 安定なポリミキシン系抗生物質水性溶液 |
| IL96432A0 (en) | 1989-11-30 | 1991-08-16 | Schering Ag | Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives |
| FR2662163A1 (fr) | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
| DK0649425T3 (da) | 1992-06-17 | 1999-09-27 | Upjohn Co | Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester |
| JP2923139B2 (ja) | 1992-10-05 | 1999-07-26 | 三井化学株式会社 | 製 剤 |
| DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| AU9651198A (en) | 1997-11-11 | 1999-05-31 | Ono Pharmaceutical Co. Ltd. | Fused pyrazine compounds |
| JP2000319277A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| JP2000319278A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| JP4032566B2 (ja) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | 発光素子 |
| JP4041624B2 (ja) | 1999-07-21 | 2008-01-30 | 三井化学株式会社 | 有機電界発光素子 |
| JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
| IL148864A0 (en) | 1999-09-28 | 2002-09-12 | Panacea Biotec Ltd | Pharmaceutical compositions containing nimesulide |
| SE9903611D0 (sv) | 1999-10-06 | 1999-10-06 | Astra Ab | Novel compounds III |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| JP4409680B2 (ja) | 1999-10-18 | 2010-02-03 | 株式会社ヤクルト本社 | 三環性縮合イミダゾール誘導体 |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| JP3729343B2 (ja) | 2000-04-27 | 2005-12-21 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| WO2002034748A1 (fr) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Derives d'imidazopyridine |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| CA2427779A1 (en) | 2000-11-10 | 2002-05-16 | Merck Sharp & Dohme Limited | Imidazo-triazine derivatives as ligands for gaba receptors |
| US20040058938A1 (en) | 2000-12-13 | 2004-03-25 | Oliver Cullmann | Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| EP1377549A1 (en) | 2001-03-12 | 2004-01-07 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| WO2005014777A2 (en) | 2002-10-16 | 2005-02-17 | Board Of Regents, The University Of Texas System | Methods and compositions for increasing the efficacy of biologically-active ingredients |
| WO2004058176A2 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Acyclic pyrazole compounds |
| US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| ES2338656T3 (es) | 2003-04-11 | 2010-05-11 | High Point Pharmaceuticals, Llc | Uso farmaceutico de 1,2,4-triazoles fusionados. |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| AU2004233828B2 (en) | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| ATE551997T1 (de) | 2003-09-12 | 2012-04-15 | Merck Serono Sa | Sulfonamid-derivate zur behandlung von diabetes |
| JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| JP2007508290A (ja) | 2003-10-10 | 2007-04-05 | ファイザー・プロダクツ・インク | ＧＳＫ−３阻害剤としての置換２Ｈ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| US7714009B2 (en) | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| WO2005063241A1 (ja) | 2003-12-26 | 2005-07-14 | Ono Pharmaceutical Co., Ltd. | ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤 |
| EP1717238A4 (en) | 2004-02-16 | 2008-03-05 | Daiichi Seiyaku Co | FUNGICIDES HETEROCYCLIC COMPOUNDS |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| MXPA06012449A (es) * | 2004-04-26 | 2007-01-17 | Pfizer | Inhibidores de la enzima integrasa de vih. |
| EP2258349B1 (en) | 2004-05-11 | 2014-07-16 | Egalet Ltd. | Swellable dosage form comprising gellan gum |
| TW200612918A (en) | 2004-07-29 | 2006-05-01 | Threshold Pharmaceuticals Inc | Lonidamine analogs |
| EP1781655A2 (en) | 2004-08-18 | 2007-05-09 | Pharmacia & Upjohn Company LLC | Triazolopyridine compounds useful for the treatment of inflammation |
| JP2008511669A (ja) | 2004-09-02 | 2008-04-17 | スミスクライン ビーチャム コーポレーション | 化合物 |
| US7524860B2 (en) | 2004-10-07 | 2009-04-28 | Pfizer Inc. | Antibacterial agents |
| AU2005309761A1 (en) | 2004-11-22 | 2006-06-01 | Threshold Pharmaceuticals, Inc. | Tubulin binding anti cancer agents and prodrugs thereof |
| ATE443063T1 (de) | 2004-12-01 | 2009-10-15 | Merck Serono Sa | Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen |
| US20070293456A9 (en) | 2004-12-30 | 2007-12-20 | Anthony Hayford | Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| NZ556627A (en) | 2005-02-22 | 2010-09-30 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| EP1901748B1 (en) | 2005-06-09 | 2010-09-08 | Oncalis AG | Angiogenesis inhibitors |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| TW200726765A (en) | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| TWI255587B (en) | 2005-07-04 | 2006-05-21 | Quanta Comp Inc | Multi-frequency planar antenna |
| US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
| EP1931641B1 (en) | 2005-09-09 | 2010-08-25 | Schering Corporation | NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHI |
| WO2007058942A2 (en) | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| BRPI0620760A2 (pt) | 2005-12-27 | 2011-11-22 | Hoffmann La Roche | derivados de aril-isoxazol-4-il-imidazo[1,5]piridina |
| WO2007074491A1 (en) | 2005-12-28 | 2007-07-05 | Universita Degli Studi Di Siena | HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| US8097617B2 (en) | 2006-03-31 | 2012-01-17 | Novartis Ag | Organic compounds |
| MX2008015747A (es) | 2006-06-06 | 2008-12-19 | Schering Corp | Imidazopirazinas como inhibidores de la proteina quinasa. |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| JP2009541323A (ja) | 2006-06-22 | 2009-11-26 | マリンクロット インコーポレイテッド | 拡張された共役を有するピラジン誘導体およびその使用 |
| JP2009534396A (ja) | 2006-06-22 | 2009-09-24 | マリンクロッド・インコーポレイテッド | ピラジン誘導体および腎臓の監視におけるその使用 |
| KR20090031544A (ko) | 2006-06-29 | 2009-03-26 | 쉐링 코포레이션 | 치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제 |
| WO2008005423A1 (en) | 2006-07-03 | 2008-01-10 | Cambrex Charles City, Inc. | Improved method of making sufentanil |
| US7501438B2 (en) | 2006-07-07 | 2009-03-10 | Forest Laboratories Holdings Limited | Pyridoimidazole derivatives |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| WO2008011557A2 (en) | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
| WO2008027812A2 (en) | 2006-08-28 | 2008-03-06 | Forest Laboratories Holdings Limited | Imidazopyridine and imidazopyrimidine derivatives |
| DE102006041292A1 (de) | 2006-09-01 | 2008-03-06 | Henkel Kgaa | Wasserstoffperoxid-Aktivierung mit N-Heterocyclen |
| WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
| AU2007307031B2 (en) | 2006-10-11 | 2011-11-24 | Amgen Inc. | Imidazo- and triazolo-pyridine compounds and methods of use therof |
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| AU2007323996A1 (en) | 2006-11-08 | 2008-05-29 | Novavax, Inc. | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
| KR101532256B1 (ko) | 2006-11-22 | 2015-06-29 | 인사이트 코포레이션 | 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘 |
| JP2010511018A (ja) | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物 |
| EP2063867A2 (en) | 2006-12-22 | 2009-06-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| JP5612860B2 (ja) | 2007-03-09 | 2014-10-22 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体 |
| DE102007012645A1 (de) | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| EP1972628A1 (en) | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as CNS active compounds |
| JP2010523725A (ja) | 2007-04-16 | 2010-07-15 | レオ ファーマ アクティーゼルスカブ | 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン |
| JP2010524953A (ja) | 2007-04-17 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤 |
| CN101855222A (zh) | 2007-05-10 | 2010-10-06 | 通用电气健康护理有限公司 | 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物 |
| WO2008143240A1 (ja) | 2007-05-21 | 2008-11-27 | Toray Industries, Inc. | 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 |
| SG182187A1 (en) | 2007-06-08 | 2012-07-30 | Abbott Gmbh & Co Kg | 5-heteroaryl substituted indazoles as kinase inhibitors |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| CN101772500A (zh) | 2007-06-14 | 2010-07-07 | 先灵公司 | 作为蛋白质激酶抑制剂的咪唑并吡嗪 |
| CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
| US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
| KR20100049073A (ko) | 2007-07-18 | 2010-05-11 | 노파르티스 아게 | 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도 |
| EP2182986A2 (en) | 2007-07-31 | 2010-05-12 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| US20090176778A1 (en) | 2007-08-10 | 2009-07-09 | Franz Ulrich Schmitz | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| US20090047336A1 (en) | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
| FR2920090A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier. |
| FR2920091A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier. |
| KR20090022616A (ko) | 2007-08-31 | 2009-03-04 | 한올제약주식회사 | 베실산클로피도그렐 함유 경구투여용 약제 |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2008309383B2 (en) | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
| TW200927142A (en) | 2007-10-12 | 2009-07-01 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators |
| PL2231662T3 (pl) | 2007-12-19 | 2011-11-30 | Genentech Inc | 8-anilinoimidazopirydyny oraz ich zastosowanie jako czynników przeciwnowotworowych i/lub przeciwzapalnych |
| CL2008003798A1 (es) | 2007-12-19 | 2009-10-09 | Amgen Inc | Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades. |
| KR100988233B1 (ko) | 2007-12-26 | 2010-10-18 | 한미홀딩스 주식회사 | 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 |
| PL2288610T3 (pl) | 2008-03-11 | 2017-12-29 | Incyte Holdings Corporation | Azetydynowe i cyklobutanowe pochodne jako inhibitory jak |
| WO2009114181A2 (en) | 2008-03-12 | 2009-09-17 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines solid |
| JP5638961B2 (ja) | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Ｂｍｐシグナル伝達経路のインヒビター |
| JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン， エルエルシー | キナーゼ阻害剤および使用方法 |
| EP2444403A1 (en) | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
| DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
| US8349210B2 (en) | 2008-06-27 | 2013-01-08 | Transitions Optical, Inc. | Mesogenic stabilizers |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
| WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| JP2010070503A (ja) | 2008-09-19 | 2010-04-02 | Daiichi Sankyo Co Ltd | 抗真菌作用２−アミノトリアゾロピリジン誘導体 |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| ES2403633T3 (es) | 2008-12-04 | 2013-05-20 | Proximagen Limited | Compuestos de imidazopiridina |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| CA2750517A1 (en) | 2009-02-04 | 2010-08-12 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CA2749933A1 (en) | 2009-02-04 | 2010-08-12 | Supernus Pharmaceuticals, Inc. | Formulations of desvenlafaxine |
| TR200900878A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
| TR200900879A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler |
| JP5667085B2 (ja) | 2009-02-13 | 2015-02-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ａｋｔインヒビターとしての融合されたピリミジン |
| KR20100101055A (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물 |
| WO2010107404A1 (en) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
| US8481732B2 (en) | 2009-03-20 | 2013-07-09 | Incyte Corporation | Substituted heterocyclic compounds |
| HRP20130846T1 (hr) | 2009-03-31 | 2013-11-22 | Kissei Pharmaceutical Co., Ltd. | Derivati indolizina i njihova uporaba u medicinske svrhe |
| CA2756759C (en) | 2009-04-16 | 2017-11-07 | Joaquin Pastor Fernandez | Imidazopyrazines for use as kinase inhibitors |
| TWI461426B (zh) | 2009-05-27 | 2014-11-21 | Merck Sharp & Dohme | （二氫）咪唑並異〔５，１－ａ〕喹啉類 |
| JP2012529529A (ja) | 2009-06-10 | 2012-11-22 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法 |
| US8686009B2 (en) | 2009-06-25 | 2014-04-01 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
| GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| EP2473495A1 (en) | 2009-09-18 | 2012-07-11 | Almac Discovery Limited | Pharmaceutical compounds |
| JP5699152B2 (ja) | 2009-09-25 | 2015-04-08 | オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． | リジン特異的デメチラーゼ−１阻害剤およびその使用 |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| US8614315B2 (en) | 2009-12-25 | 2013-12-24 | Mahmut Bilgic | Cefdinir and cefixime formulations and uses thereof |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| US20130085133A1 (en) | 2010-02-08 | 2013-04-04 | Sourthern Research Institute Office of Commercialization and Intellectual Prop. | Anti-viral treatment and assay to screenfor anti-viral agent |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| CN102971321B (zh) | 2010-03-18 | 2015-07-29 | 拜耳知识产权有限责任公司 | 咪唑并吡嗪 |
| ES2572387T3 (es) | 2010-03-18 | 2016-05-31 | Pasteur Institut Korea | Compuestos anti-infecciosos |
| MX342161B (es) | 2010-04-02 | 2016-09-19 | Euroscreen Sa | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. |
| JP5868948B2 (ja) | 2010-04-19 | 2016-02-24 | オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． | リジン特異的脱メチル化酵素１阻害薬およびその使用 |
| ES2564352T3 (es) | 2010-04-20 | 2016-03-22 | Università Degli Studi Di Roma "La Sapienza" | Derivados de tranilcipromina como inhibidores de la histona-desmetilasa LSD1 y/o LSD2 |
| KR20130065632A (ko) | 2010-04-28 | 2013-06-19 | 다이이찌 산쿄 가부시키가이샤 | ［５，６］복소 고리 화합물 |
| SG185515A1 (en) | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| CN102247321A (zh) | 2010-05-20 | 2011-11-23 | 上海亚盛医药科技有限公司 | 一种阿朴棉子酚酮自乳化药物传递系统及其制备方法 |
| WO2011149438A1 (en) | 2010-05-28 | 2011-12-01 | Mahmut Bilgic | Combination of antihypertensive agents |
| CN102295642B (zh) | 2010-06-25 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途 |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| US8975265B2 (en) | 2010-07-12 | 2015-03-10 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-a]pyrimidines and —pyridines |
| WO2012009475A1 (en) | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| CN101987082B (zh) | 2010-07-16 | 2013-04-03 | 钟术光 | 固体制剂及其制备方法 |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| CN102397552B (zh) | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
| KR20130099064A (ko) | 2010-09-29 | 2013-09-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | (아자)인돌리진 유도체 및 그 의약용도 |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| JP2013540767A (ja) | 2010-10-07 | 2013-11-07 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 免疫不全ウイルス転写を調節するための組成物および方法 |
| AU2011318398B2 (en) | 2010-10-18 | 2015-09-10 | E. I. Du Pont De Nemours And Company | Nematocidal sulfonamides |
| TWI557123B (zh) | 2010-10-21 | 2016-11-11 | 梅迪維新技術公司 | 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽 |
| WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
| JP5824065B2 (ja) | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| CN103429592A (zh) | 2010-12-17 | 2013-12-04 | 拜耳知识产权有限责任公司 | 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪 |
| EP2651950A1 (en) | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| TWI617559B (zh) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物 |
| EP2665726A4 (en) | 2011-01-21 | 2014-09-03 | Gen Hospital Corp | COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES |
| BRPI1100101B1 (pt) | 2011-01-28 | 2020-10-20 | Universidade De São Paulo Usp | anel oito articulado |
| EP2712316A1 (en) | 2011-02-08 | 2014-04-02 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| JP5813855B2 (ja) | 2011-03-25 | 2015-11-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｌｓｄ１阻害剤としてのシクロプロピルアミン |
| WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| US20140329833A1 (en) | 2011-05-19 | 2014-11-06 | Oryzon Genomics, S.A | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| CN103687496A (zh) | 2011-06-07 | 2014-03-26 | Spai集团有限公司 | 用于改善敏感性食品添加剂及其食品产品的稳定性并且延长其货架期的组合物和方法 |
| PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| TW201311149A (zh) | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | 有害生物防治劑 |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| CN103842332B (zh) | 2011-08-09 | 2016-08-17 | 武田药品工业株式会社 | 环丙胺化合物 |
| WO2013025805A1 (en) | 2011-08-15 | 2013-02-21 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
| US9289415B2 (en) | 2011-09-01 | 2016-03-22 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US9273343B2 (en) | 2011-09-02 | 2016-03-01 | Promega Corporation | Compounds and methods for assaying redox state of metabolically active cells and methods for measuring NAD(P)/NAD(P)H |
| HK1211023A1 (zh) | 2011-10-10 | 2016-05-13 | H. Lundbeck A/S | 具有咪唑并吡嗪骨架pde9i |
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| CL2014000988A1 (es) | 2011-10-20 | 2014-11-03 | Oryzon Genomics Sa | Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia. |
| SG11201401066PA (en) | 2011-10-20 | 2014-10-30 | Oryzon Genomics Sa | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| ITMI20111971A1 (it) | 2011-10-28 | 2013-04-29 | Mesogenics Srl | Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico |
| EP2785183B1 (en) | 2011-11-14 | 2018-12-19 | Merck Sharp & Dohme Corp. | Triazolopyridinone pde10 inhibitors |
| EP2787990A4 (en) | 2011-12-05 | 2015-09-02 | Univ Brandeis | TREATMENT OF AMYLOIDOSE BY COMPOUNDS FOR REGULATING RETROMER STABILIZATION |
| HK1203948A1 (en) | 2012-03-07 | 2015-11-06 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| CN102579381B (zh) | 2012-03-30 | 2013-07-10 | 河南中帅医药科技发展有限公司 | 盐酸胍法辛缓释制剂及其制备方法 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
| US9611267B2 (en) * | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| EP2867226B1 (en) | 2012-06-28 | 2018-11-14 | Novartis AG | Complement pathway modulators and uses thereof |
| CN102772444A (zh) | 2012-07-06 | 2012-11-14 | 周明千 | 中药超微破壁口服片剂饮片的加工方法 |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| DK2900238T3 (en) | 2012-09-28 | 2018-03-12 | Univ Vanderbilt | CONDENSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS |
| CN104837832B (zh) | 2012-10-05 | 2019-04-26 | 里格尔药品股份有限公司 | Gdf-8抑制剂 |
| WO2014058071A1 (ja) | 2012-10-12 | 2014-04-17 | 武田薬品工業株式会社 | シクロプロパンアミン化合物およびその用途 |
| EP2919770A4 (en) | 2012-11-14 | 2017-03-08 | The Board of Regents of The University of Texas System | Inhibition of hif-2 heterodimerization with hif1 (arnt) |
| JP6238908B2 (ja) | 2012-11-28 | 2017-11-29 | 京都府公立大学法人 | リシン構造を有するｌｓｄ１選択的阻害薬 |
| EP2925307B1 (en) | 2012-11-30 | 2020-10-28 | McCord, Darlene E. | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| MX360420B (es) | 2012-12-19 | 2018-10-31 | Wockhardt Ltd | Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma. |
| CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
| CN103933036B (zh) | 2013-01-23 | 2017-10-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途 |
| JP2016513112A (ja) | 2013-02-18 | 2016-05-12 | ザ スクリプス リサーチ インスティテュート | 治療的潜在能力を有するバソプレッシン受容体のモジュレーター |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| US20160050895A1 (en) | 2013-03-13 | 2016-02-25 | Australian Nuclear Science And Technology Organization | Transgenic non-human organisms with non-functional tspo genes |
| EP2968343A4 (en) | 2013-03-14 | 2016-11-02 | Epizyme Inc | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
| US20140343118A1 (en) | 2013-03-14 | 2014-11-20 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| WO2014194280A2 (en) | 2013-05-30 | 2014-12-04 | The Board of Regents of the Nevada System of Higher Education on behalf of the University of | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
| CA2915817C (en) | 2013-06-19 | 2022-12-13 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
| US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
| JP2016531151A (ja) | 2013-09-13 | 2016-10-06 | バイエル ファーマ アクチエンゲゼルシャフト | レファメチニブを含有する医薬組成物 |
| KR101568724B1 (ko) | 2013-11-13 | 2015-11-12 | 서울대학교산학협력단 | 신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도 |
| CA3161836A1 (en) | 2013-12-11 | 2015-06-18 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US9493450B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| WO2015145145A1 (en) | 2014-03-24 | 2015-10-01 | Cipla Limited | Pharmaceutical composition comprising lapatinib |
| CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
| EA028942B1 (ru) | 2014-04-02 | 2018-01-31 | Бристол-Майерс Сквибб Компани | Биарильные ингибиторы киназы |
| WO2015155281A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
| WO2015155297A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and h2-receptor antagonists |
| PE20161441A1 (es) | 2014-04-11 | 2017-01-21 | Takeda Pharmaceuticals Co | Compuesto de ciclopropanamina y sus usos |
| CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
| JP6320570B2 (ja) | 2014-05-30 | 2018-05-09 | イエオ−イスティトゥート・エウロペオ・ディ・オンコロジア・エッセ・エッレ・エッレ | ヒストンデメチラーゼ阻害剤としてのシクロプロピルアミン化合物 |
| CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| CN104173313B (zh) | 2014-08-25 | 2017-05-17 | 杭州朱养心药业有限公司 | 利伐沙班片剂药物组合物 |
| JP6653116B2 (ja) | 2014-08-27 | 2020-02-26 | 日本ケミファ株式会社 | オルメサルタンのプロドラッグ製剤 |
| PE20171057A1 (es) | 2014-10-08 | 2017-07-21 | Hoffmann La Roche | Derivados espirodiamina como inhibidores de la aldosterona sintasa |
| PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
| BR112017020935A2 (pt) | 2015-04-03 | 2018-07-10 | Mutabilis | ?compostos, composição farmacêutica e conjunto? |
| AU2016242978A1 (en) | 2015-04-03 | 2017-11-23 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| CN112656772B (zh) | 2015-10-15 | 2022-05-20 | 浙江东日药业有限公司 | 利伐沙班药物组合物 |
| US9809541B2 (en) | 2015-12-29 | 2017-11-07 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| WO2017130933A1 (ja) | 2016-01-25 | 2017-08-03 | 国立大学法人熊本大学 | 神経変性疾患治療剤 |
| CN109414410B (zh) | 2016-04-22 | 2022-08-12 | 因赛特公司 | Lsd1抑制剂的制剂 |
| JP2020511424A (ja) | 2017-01-18 | 2020-04-16 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 選択的ｂｍｐ阻害としての縮合複素環式化合物 |
| RU2764655C2 (ru) | 2017-03-16 | 2022-01-19 | Цзянсу Хэнжуй Медицин Ко., Лтд. | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ |
| CN113166153B (zh) | 2018-07-05 | 2024-11-01 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
-
2015
- 2015-02-12 PE PE2016001466A patent/PE20161573A1/es unknown
- 2015-02-12 US US14/620,903 patent/US9670210B2/en active Active
- 2015-02-12 TW TW104104827A patent/TWI685483B/zh active
- 2015-02-12 SG SG11201606689VA patent/SG11201606689VA/en unknown
- 2015-02-12 MY MYPI2016001506A patent/MY183499A/en unknown
- 2015-02-12 SM SM20190680T patent/SMT201900680T1/it unknown
- 2015-02-12 PH PH1/2020/552066A patent/PH12020552066A1/en unknown
- 2015-02-12 ME MEP-2019-327A patent/ME03654B/me unknown
- 2015-02-12 AU AU2015217073A patent/AU2015217073B2/en active Active
- 2015-02-12 ES ES15706634T patent/ES2760261T3/es active Active
- 2015-02-12 KR KR1020167025508A patent/KR102421235B1/ko active Active
- 2015-02-12 PT PT157066341T patent/PT3105218T/pt unknown
- 2015-02-12 CR CR20200199A patent/CR20200199A/es unknown
- 2015-02-12 HU HUE15706634A patent/HUE046273T2/hu unknown
- 2015-02-12 CN CN201911356925.9A patent/CN111454188A/zh active Pending
- 2015-02-12 ES ES19190494T patent/ES2901711T3/es active Active
- 2015-02-12 SG SG10201806849WA patent/SG10201806849WA/en unknown
- 2015-02-12 LT LT15706634T patent/LT3105218T/lt unknown
- 2015-02-12 JP JP2016551710A patent/JP6602778B2/ja active Active
- 2015-02-12 EP EP15706634.1A patent/EP3105218B1/en active Active
- 2015-02-12 HR HRP20192167TT patent/HRP20192167T1/hr unknown
- 2015-02-12 CA CA2939082A patent/CA2939082C/en active Active
- 2015-02-12 CR CR20160396A patent/CR20160396A/es unknown
- 2015-02-12 UA UAA201609400A patent/UA126541C2/uk unknown
- 2015-02-12 PL PL15706634T patent/PL3105218T3/pl unknown
- 2015-02-12 DK DK15706634T patent/DK3105218T3/da active
- 2015-02-12 EP EP19190494.5A patent/EP3626713B1/en active Active
- 2015-02-12 CN CN201580017095.0A patent/CN106164066B/zh active Active
- 2015-02-12 WO PCT/US2015/015706 patent/WO2015123465A1/en not_active Ceased
- 2015-02-12 SI SI201530920T patent/SI3105218T1/sl unknown
- 2015-02-12 SG SG10201908028S patent/SG10201908028SA/en unknown
- 2015-02-12 MX MX2016010395A patent/MX377273B/es active IP Right Grant
- 2015-02-12 RS RS20191486A patent/RS59559B1/sr unknown
- 2015-02-12 TW TW109101686A patent/TWI741478B/zh active
-
2016
- 2016-08-07 IL IL247134A patent/IL247134B/en active IP Right Grant
- 2016-08-10 MX MX2020012046A patent/MX2020012046A/es unknown
- 2016-08-11 PH PH12016501601A patent/PH12016501601A1/en unknown
- 2016-08-11 CL CL2016002027A patent/CL2016002027A1/es unknown
- 2016-09-09 EC ECIEPI201673190A patent/ECSP16073190A/es unknown
- 2016-09-09 ZA ZA2016/06275A patent/ZA201606275B/en unknown
-
2017
- 2017-04-26 US US15/497,887 patent/US10174030B2/en active Active
-
2018
- 2018-11-19 US US16/195,026 patent/US10717737B2/en active Active
-
2019
- 2019-08-01 AU AU2019210624A patent/AU2019210624B2/en not_active Ceased
- 2019-10-09 JP JP2019185892A patent/JP6883635B2/ja not_active Expired - Fee Related
- 2019-12-12 CY CY20191101308T patent/CY1122415T1/el unknown
-
2020
- 2020-06-09 US US16/897,051 patent/US11247992B2/en not_active Expired - Fee Related
- 2020-09-06 IL IL277167A patent/IL277167B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510554A5 (enExample) | ||
| JP2017510555A5 (enExample) | ||
| RU2018115722A (ru) | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ | |
| JP5263304B2 (ja) | アミノピラジン誘導体及び医薬 | |
| JP2018529743A5 (enExample) | ||
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| JP2017506659A5 (enExample) | ||
| JP2012501312A5 (enExample) | ||
| SI2790705T1 (en) | Use of activity inhibitors or PI3K function | |
| JP2016536333A5 (enExample) | ||
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| JP2013528204A5 (enExample) | ||
| JP2019523233A5 (enExample) | ||
| EA032609B1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| JP2011500806A5 (enExample) | ||
| RU2018142987A (ru) | Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m4 | |
| IL288243B2 (en) | Heteroaryl-substituted pyridines and methods of use | |
| RU2010106974A (ru) | Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3 | |
| JP2015500862A5 (enExample) | ||
| JP2019526616A5 (enExample) | ||
| HRP20192033T1 (hr) | Ciklopropilamini kao lsd1 inhibitori | |
| JP2012515761A5 (enExample) | ||
| JP2005529092A5 (enExample) | ||
| HUE033177T2 (en) | Pyrazine carboxamide compound | |
| JP2013515688A (ja) | Ｊａｋ阻害剤としてのイミダゾピリジン誘導体 |